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Background: Intrinsic resistance to androgen receptor signalling inhibitors (ARSI) occurs in 2030% of men
with metastatic castration-resistant prostate cancer (mCRPC). Ceramide metabolism may have a role in ARSI
resistance. Our study’s aim is to investigate the association of the ceramide-sphingosine-1-phosphate (cer-
amide-S1P) signalling axis with ARSI resistance in mCRPC.
Methods: Lipidomic analysis (»700 lipids) was performed on plasma collected from 132 men with mCRPC,
before commencing enzalutamide or abiraterone. AR gene aberrations in 77 of these men were identified by
deep sequencing of circulating tumour DNA. Associations between circulating lipids, radiological progres-
sion-free survival (rPFS) and overall survival (OS) were examined by Cox regression. Inhibition of ceramide-
S1P signalling with sphingosine kinase (SPHK) inhibitors (PF-543 and ABC294640) on enzalutamide efficacy
was investigated with in vitro assays, and transcriptomic and lipidomic analyses of prostate cancer (PC) cell
lines (LNCaP, C42B, 22Rv1).
Findings: Men with elevated circulating ceramide levels had shorter rPFS (HR=2¢3, 95% CI=1¢53¢6,
p = 0¢0004) and shorter OS (HR=2¢3, 95% CI=1¢436, p = 0¢0005). The combined presence of an AR aberration
with elevated ceramide levels conferred a worse prognosis than the presence of only one or none of these
characteristics (median rPFS time = 3¢9 vs 8¢3 vs 17¢7 months; median OS time = 8¢9 vs 19¢8 vs 34¢4 months).
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Interpretation: Ceramide-S1P signalling promotes ARSI resistance, which can be reversed with SPHK
inhibitors.
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erapy may be identi-1. Introduction
Prostate cancer (PC) is the second most common cancer and the
fifth leading cause of cancer death in men worldwide [1]. In the last
decade, substantial progress has been made in the treatment of meta-
static castration-resistant prostate cancer (mCRPC) with the emer-
gence of novel androgen receptor signalling inhibitor (ARSI) therapy
such as enzalutamide (ENZ) and abiraterone [25]. However,resistance to ARSI is a major clinical challenge, with intrinsic resis-
tance affecting 2030% of patients, and acquired resistance being the
ultimate outcome for all patients on ARSI therapy [6]. Mechanisti-
cally, ARSI resistance has been linked to androgen receptor (AR) gene
aberrations such as copy number gain and mutations [7], which can
be detected in circulating cell-free DNA (cfDNA) [8]. Conversely, ARSI
usage can lead to the emergence of AR-negative disease, such as neu-
roendocrine prostate cancer which lacks targeted treatment and is
invariably fatal [9]. Identifying novel therapies to overcome ARSI
resistance is therefore critical to improve patient outcomes.
A novel approach to understanding ARSI resistance is to consider
the role of sphingolipids, which are a class of lipids characterised by a
sphingosine backbone, and regulate various biological processes
including cell growth and inflammation [1012]. Epidemiological
evidence indicate that statin therapy is associated with improved
overall survival (OS) in PC [13,14], which was also demonstrated for
its concomitant use with abiraterone [15,16] and androgen depriva-
tion therapy [17]. However, blood cholesterol levels were not associ-
ated with PC death [18] or risk of recurrence after radical
prostatectomy [19,20], indicating that the beneficial effects of statin
in PC is not necessarily related to its cholesterol-lowering mecha-
nism. A possible alternate mechanism is the ability of statin to lower
the circulating levels of ceramides, a type of sphingolipid [2123].
Our previous lipidomic studies had shown that elevated circulat-
ing levels of ceramides were associated with earlier androgen depri-
vation therapy (ADT) failure in metastatic hormone-sensitive PC,
shorter progression-free survival (PFS) after docetaxel in mCRPC, and
shorter OS in mCRPC [24,25]. Ceramide can be metabolised into
sphingosine-1-phosphate (S1P), which can promote cancer growth,
metastasis and drug resistance by activating specific G-protein-cou-
pled receptors to regulate cell proliferation, survival and the immune
response [1012]. Ceramide and S1P may also be involved in steroid
synthesis and function through the regulation of steroidogenic gene
transcription [26], by acting as ligands of nuclear receptors or as intra-
cellular secondary messengers [2729]. The liver is the main source
of circulating ceramides [30], but cancer cells also express enzymes
involved in de novo ceramide synthesis and the metabolism of ceram-
ides into S1P, as well as S1P receptors [10]. Thus, we hypothesise that
the ceramide-S1P signalling axis may be promoting poor prognosis
disease in PC and may be contributing to ARSI resistance.
Metabolism of ceramides into S1P requires the conversion of cer-
amide into sphingosine, which is phosphorylated by sphingosine
kinase (SPHK) into S1P (Fig. 1a). The ceramide-S1P signalling axis can
be therapeutically targeted by chemical inhibition of SPHK to prevent
the production of S1P [31]. SPHK exists as two isoforms  SPHK1
(cytoplasmic) and SPHK2 (nuclear) [32]. Various cancer tissues
including PC have higher expression of SPHK1 compared to normal
[33,34], where high SPHK1 expression was associated with shorter
survival (no data for PC)(34). Inhibition of either SPHK1 or SPHK2 in
various cancers including PC resulted in anti-tumour effects in vitro
and in vivo [10,35,36]. SPHK1 inhibition also enhanced docetaxel sen-
sitivity in PC cell lines [37]. Androgen deprivation of PC cells increased
SPHK1 expression and activity, which may contribute to androgen-
independent survival [38]. However, the role of SPHK as a potential
target to overcome ARSI therapy resistance has not been studied.
Our study aimed to investigate the relationship between the cer-
amide-S1P signalling axis and ARSI resistance in mCRPC, by (Aim 1)
profiling circulating lipids and AR aberrations in mCRPC patients
Fig. 1. Elevated pre-treatment levels of circulating ceramides are associated with ARSI resistance in mCRPC: (a) ceramide-S1P signalling axis  ceramide is metabolised into sphin-
gosine-1-phosphate (S1P) which binds to specific receptors to activate signalling cascades that promote cell proliferation and survival; (b) outline of analyses on mCRPC study
cohort; (c) scoreplot of principal components analysis (PCA) of pre-treatment plasma lipidomic profiles (each datapoint represents a plasma sample); (d) hazard ratio of total lipid
levels significantly associated with rPFS or OS; (e) hazard ratio of individual levels of sphingolipid species in relation to rPFS or OS (each datapoint represents a lipid species, confi-
dence intervals only displayed for significant lipids); (f, g) Kaplan-Meier curves of rPFS and OS of men with Lipid Profile 1 versus 2; (h) heatmap of baseline plasma levels of signifi-
cant ceramide species in patients grouped by lipid profiles identified from latent class analysis (LCA).
H.-M. Lin et al. / EBioMedicine 72 (2021) 103625 3receiving ARSI, and (Aim 2) investigating the effect of SPHK inhibitors
on ENZ resistance in cell line models. We hypothesise that elevated
levels of circulating ceramides and somatic aberrations in sphingoli-
pid metabolism genes are associated with poorer response to ARSI
therapy, and may be targeted by novel therapeutic combinations.
2. Methods
2.1. Patients and plasma samples
Patients with mCRPC were recruited from medical oncology clin-
ics in academic teaching hospitals in Australia for an open-label non-interventional study investigating circulating biomarkers for any line
of mCRPC treatment. The hospitals were Chris O’Brien Lifehouse, Con-
cord Repatriation General Hospital, St Vincent’s Hospital Sydney, Mid
North Coast Cancer Institute, Sydney Adventist hospital, Epworth
HealthCare, Monash Health, and Eastern Health. Sample size calcula-
tions estimated a minimum of 94 patients is required, as our previous
study of a discovery mCRPC cohort showed that 42% have a poor
prognostic lipidomic profile [24] (Type 1 error rate = 5%, deviation
from true proportion = 5%); in addition, a minimum of 73 patients is
required to achieve a 25% prevalence of ARSI resistance. 132 patients
commencing treatment with enzalutamide or abiraterone between
June 2016 to February 2020 were recruited. Patients were seen by
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cal progression was defined as by the Prostate Cancer Clinical Trials
Working Group 2 [39].
Plasma samples were collected from these 132 patients prior to
commencing treatment, according to a standardised blood collection
protocol  blood was collected in EDTA-containing tubes and centri-
fuged at 1600 £ g within 1 h of collection to separate the plasma,
which was then transferred to fresh tubes and centrifuged again at
5000 £ g for 10 min. Aliquots of the plasma after the second spin
were stored at -70 °C until required.2.2. Ethics
All participants provided written informed consent. The study
was approved for Monash Health and Eastern Health by the Monash
Health Institutional Review Board (Reference number: 15571X), and
approved for the other sites by Royal Prince Alfred Hospital human
research ethics committee (Reference numbers: X19-0320 & 2019/
ETH12152).2.3. Plasma lipidomic analysis
Lipidomic profiling of plasma samples was performed by liquid
chromatography-mass spectrometry (LC-MS) as previously described
[40]. The data was normalised using the Probabilistic Quotient Nor-
malisation method as previously described [25], with final lipid levels
transformed to logarithm-2 of pmol/ml for statistical analysis. Tar-
geted analysis of selected lipids in the same plasma aliquots using
alternative independent methods (immunoassay and targeted LC-
MS) confirmed the validity of the lipidomic measurements (Supple-
mentary Information S1.7).2.4. Next-generation sequencing of cfDNA
Extraction of plasma cfDNA, next-generation sequencing and bio-
informatics analysis was performed as previously described [41]. To
summarise, extracted cfDNA underwent library preparation, panel-
based hybridisation (Predicine, Inc.) and enrichment, followed by
paired-end sequencing on the Illumina HiSeq Xten. Point mutations,
small insertions/deletions (10 bp) and copy number alterations
were identified using Predicine’s proprietary GeneRADAR technology
and DeepSea machine learning bioinformatics algorithm.2.5. Drugs and cell lines
PF-543 (PF5), ABC294640 (ABC) and enzalutamide (ENZ) were
purchased from Selleck Chemicals. All three drugs were prepared as
20 mM stocks in dimethyl sulfoxide (DMSO) and stored in aliquots at
-20 °C. The drugs were diluted accordingly in culture media for in
vitro assays, with the matching percentage of DMSO as the vehicle
control treatment. PC cell lines LNCaP (RRID: CVCL_1379), C42B
(RRID: CVCL_4784) and 22Rv1 (RRID: CVCL_1045) were acquired
from the American Type Culture Collection (Manassas, VA, USA). The
cells were cultured in RPMI 1640 containing 10% fetal bovine serum,
and used in experiments between 2 and 10 passages after thawing
from cryostorage. The cells were routinely tested for mycoplasma
contamination (last test: 4 November 2019). The identity of cell lines
were verified by analysis of microsatellite profiles (Garvan Molecular
Genetics, Darlinghurst, NSW). Unless stated otherwise, cells were cul-
tured in 6 well plates for assays with 2 ml of culture media per well,
and treated with drug(s) the next day by replacing 1 ml of of the
media with fresh media containing the drug(s).2.6. Cell viability assay
Cells were seeded in 96 well plates at the following densities in
80 ml media per well: C42B  1200 cells/well, LNCaP  4500 cells/-
well, 22Rv1  4500 cells/well. The next day, 40 ml of fresh media
containing ENZ, PF5, ABC, or DMSO (vehicle control) were added to
each well of the cultures (final volume per well = 160 ml). After 96 h,
cell viability was assessed with Alamar Blue (Invitrogen) by fluores-
cence measurement according to manufacturer’s instructions.
2.7. Colony forming assay
Cells were seeded in 6 well plates at the following densities in
2 ml media per well: C42B and 22Rv1 500 cells/well, LNCaP 
2000 cells/well. The next day, ENZ, PF5, ABC or DMSO (vehicle con-
trol) were added to the cultures. After 1 week from seeding, culture
media was refreshed without drugs. After 2 weeks from seeding, cells
were fixed with 16% trichloroacetic acid for 30 min. After fixation,
cells were stained with Quick Dip II (Fronine) for 30 min, and rinsed
with water until the rinse was clear of excess stain. Images of the
wells were taken and colonies were counted using ImageJ (National
Institutes of Health, U.S.A).
2.8. Flow cytometry of apoptosis and cell cycle
Cells were seeded in 6 well plates at the following densities in
2 ml media per well: C42B  2¢2 £ 105 cells/well, LNCaP  5 £ 105
cells/well, 22Rv1  3¢8 £ 105 cells/well. The next day, the media
from each well was replaced with fresh media containing drug(s) or
DMSO vehicle control. After 48 h of treatment, cells were collected
for apoptosis or cell cycle analysis. Floating cells in the conditioned
media were collected by centrifugation whereas adherent cells were
detached with trypsin. Cells were labelling for apoptosis analysis
using the AnnexinV-FITC Apoptosis Detection kit (BioVision Research
Products, USA) according to manufacturer’s instructions. Cells were
labelled for cell cycle analysis by fixing in 70% ethanol at -20 °C for at
least 24 h, followed by washing with phosphate-buffered saline
(PBS), then incubation with 0.1% propidium iodide and 830 mg/ml
RNase A (Sigma) for at least 4 h. Flow cytometry analyses were per-
formed on the BD FACS Canto II system (BD Biosciences) using the
FACSDiva software version 8. Data was analysed with FlowJo version
7.6.5.
2.9. Western blot
Whole cell lysates for Western Blot were prepared by scraping
cells off the culture wells in RIPA lysis buffer containing protease
cocktail inhibitor (Sigma Cat# P8340), cOmpleteTM Mini EDTA-free
protease inhibitor cocktail (Roche) and PhosStop (Roche). The cell
suspension was left on ice for 15 min and then centrifuged at
17,000 £g for 10 min at 4 °C. The supernatant (whole cell lysate) was
transferred to a fresh microtube and stored at -80 °C. The protein
concentration of the lysates was determined with the Bradford assay
(Biorad).
Nuclear fractions were prepared by gently scraping cells off cul-
ture wells in PBS, and collecting the cells by spinning with a micro-
centrifuge for 10 s. The supernatant was discarded and the cell pellet
was resuspended, by pipetting with a cut pipette tip, in a lysis buffer
of 0.1% NP40 substitute (Sigma Cat#74385) in PBS with protease/
phosphatase inhibitors as for whole cell lysates (»40 ml lysis buffer
per well of a 6 well plate). The suspension was spun on the microcen-
trifuge for 2 min, and the pellet (nuclear fraction) resuspended in
wash buffer (0.1% NP40 in PBS). The mixture was spun again for
2 min to retrieve the nuclear pellet, which was then resuspended in
loading buffer (1£x mixture of 10£ reducing agent, 4£ sample
buffer, NuPage, Invitrogen) and sonicated with a probe sonicator at
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70 °C for 10 min before loading onto gels for Western Blot (5 ml sam-
ple per well).
Precision Plus Protein Dual Color Standards (BioRad) was used as
the molecular weight marker. Protein gel electrophoresis of cell
lysates were performed with NuPAGE 412% Bis-Tris Protein Gels
and MOPS buffer according to manufacturer’s instructions (Invitro-
gen), followed by transfer to PVDF membranes. After transfer, the
membranes were blocked with 5% milk in Tris-buffered saline with
Tween 20 (TBST) for 1 h, washed with TBST multiple times (=3 rinses
repeated 4 times, 10 min soak with continuous shaking in between)
and incubated in primary antibody overnight at 4 °C with continuous
shaking. The next day, membranes were washed with TBST multiple
times, and incubated in secondary antibodies conjugated with horse
radish peroxidase (1:2000) in 5% milk for 1 h at room temperature
with continuous shaking. After secondary antibody incubation, the
membranes were washed with TBST multiple times, with the last
wash in TBS without tween.
All primary antibodies were purchased from Cell Signaling Tech-
nology and used with the stated dilution (AR, Cat#5153, clone D6F11,
rabbit, 1:1000 dilution; SPHK1, Cat#12071, RRID:AB_2797815, rabbit,
1:1000 dilution; SPHK2, Cat#32346, RRID:AB_2799021, rabbit,
1:1000 dilution; LC3B Cat#2775, RRID:AB_915950, rabbit, 1:1000
dilution; Lamin A/C, Cat#4777, RRID:AB_10545756, mouse, 1:2000
dilution) except for beta-actin (Sigma-Aldrich Cat#A5441, clone AC-
15, mouse, 1:60000 dilution) and SREBP1 (Abcam Cat#ab3259, RRID:
AB_303650, mouse, 1:200 dilution). Secondary antibodies were
Amersham ECL Mouse or Rabbit IgG, HRP-linked whole antibody
(from sheep) (Cat#NA931 & Cat#NA934, GE Healthcare Life Sciences).
Antibody binding was visualised by treating the membranes with
Western Lightning Plus-ECL enhanced chemiluminescence substrate
(PerkinElmer) and imaging with the digital imager Fusion Fx7 (Vilber
Lourmat, Germany). The primary antibody for AR has been validated
by the commercial supplier, whereas those for SPHK1, SPHK2 and
SREBP1 were validated by knockdown with synthetic small interfer-
ing RNA (siRNA) described below. Secondary antibodies are Amer-
sham ECL Mouse or Rabbit IgG, HRP-linked whole antibody (from
sheep) from GE Healthcare Life Sciences (Cat#NA931 & NA934).
2.10. siRNA knockdown
ON-TARGETplus SMARTpool human siRNA for SPHK1, SPHK2, AR
and SREBP1 (SREBF1) was purchased from Dharmacon. Reverse trans-
fection was performed with the transfection reagent DharmaFECT-1
(Dharmacon) and siRNA in either 96 well plates for cell viability
assays, or 6 well plates for preparation of cell lysates for Western
Blotting. The transfection reagents (siRNA, DharmaFECT-1, Optimem)
were mixed together, left for 20 min, and then dispensed into the
wells, prior to addition of cells (reverse transfection method). After
24 h, the culture media was replaced with fresh culture media
(exception: 48 h for SPHK1 & SPHK2). Drug treatment or preparation
of lysates for immunoblotting was performed after 48 h from the
start of transfection (Day 1 = transfection, Day 3 = drug treatment or
harvest). The volumes of siRNA/DharmaFECT-1/Optimem/cells per
well = 10/0¢07/9¢93/80 ml for 96 well plate; 200/1¢5/198¢5/1600 ml
for 6 well plate. The number of cells per well, LNCaP/C42B/
22Rv1 = 9500/3000/6000 for 96 well plate; 2¢8 £ 105/9 £ 104/
1¢8 £ 105 for 6 well plate.
2.11. Ex vivo culture of patient-derived primary prostate tissue
Fresh tissue cores (5 mm diameter) of surgically resected prostate
were obtained from patients with localised prostate cancer undergo-
ing radical prostatectomy at St Vincent's Private Hospital, Sydney (St
Vincent Hospital’s human research ethics approval reference number
12/231). The tissue cores were dissected into pieces of »1 mm3, andcultured on gelatine sponges (Spongostan Dental, Ferrosan Medical
Devices, Soeborg, Denmark) immersed in 0.5 ml culture medium
with drug(s) or matching 0¢15% DMSO vehicle control [42]. After 48 h
of culture, the explant tissues were formalin-fixed and paraffin-
embedded (FFPE). FFPE sections (4mM thickness) were co-immunos-
tained with Ki67 rabbit antibody (1:500, clone SP6, Abcam Cat#
ab16667, RRID:AB_302459) and p63 mouse antibody (1:100, Clone
DAK-p63, Dako; marker of benign basal cells) using the Leica Bond Rx
automated stainer with the ChromoPlex 1 Dual Detection kit (Leica
Biosystems). The percentage of cells stained with Ki67 was quanti-
tated by estimation.
2.12. Transcriptomic analysis of C42B cells
C42B cells were seeded in 6 well plates at 1¢4 £ 105 cells in 2 ml
media per well. After 3 days of growth (Day 4 if Day 1 is day of seed-
ing), cells were treated with drug(s) or vehicle control, with 3 repli-
cates per treatment for transcriptomic analysis. The final
concentration of each drug: 10mM ENZ, 15 mM PF5, 15 mM ABC,
0.125% DMSO. After 6 h of treatment, cells were lysed with lysis
buffer from the RNAeasy mini kit (Qiagen) (350 ml per well). The
lysates were frozen at -70 °C and total RNA extraction was continued
on another day according to the kit’s instruction. RNA quality was
assessed using the Agilent TapeStation system (Agilent). The cDNA
synthesis, labelling and hybridisation to Human Clariom S arrays (for-
merly Affymetrix)(Applied Biosystems) was performed by the Rama-
ciotti Centre for Genomics (UNSW Sydney, Australia) with the
GeneChip WT PLUS Reagent Kit as follows: starting RNA input of
100 ng per sample; hybridisation input of 2¢3 mg; hybridisation con-
ditions: 17 h, 45 °C, 60 rpm. The arrays were processed on the Affy-
metrix GeneChip Fluidics Station 45, and imaged with the Affymetrix
Affymetrix GCS3000 scanner using the Affymetrix GeneChip Com-
mand Console (AGCC) Scan Control software (v4.0.0.1567).
2.13. Real-time polymerase chain reaction (RT-PCR)
RNA was extracted from cells cultured in 6 well plates, with Trizol
Reagent (Invitrogen) according to manufacturer’s instruction with addi-
tional clean-up by sodium acetate precipitation, and stored at -80 °C.
RNA was converted into cDNA using the High Capacity Reverse Tran-
scription kit (Applied Biosystems) according to manufacturer’s instruc-
tion, with substitution of random primers with that from Invitrogen
(#48190011, final concentration in reaction = 75 ng/ml). RT-PCRwas per-
formed on the cDNA with TaqMan Gene Expression Assays (Applied
Biosystems) on Quant7 Studio (Applied Biosystems) according to
the manufacturer’s instruction. Gene expression levels were calculated
relative to beta-actin (ACTB) using the comparative CT method (2ΔΔCT).
The Taqman Gene Expression assays were Hs00358796_g1 for DDIT3,
Hs00225520_m1 for CHAC1, Hs01005622_m1 for FASN,
Hs00168352_m1 for HMGCR, Hs00957421_m1 for STARD4,
Hs99999903_m1 for ACTB, and Hs01088679_g1 for SREBF1.
2.14. Lipidomic analysis of cells
Cells were trypsinised from 6-well plates and pelleted. Lysis buffer
was prepared by adding fresh butylated hydroxytoulene (BHT) to
Tris-NaCl buffer (20 mM Tris-HCl, 500 mM NaCl, pH 7) to achieve a
final concentration of 100 mM BHT. Each cell pellet was resuspended
in 200 ml of lysis buffer and homogenised by passing the cell suspen-
sion through a 30 gauge needle 20 times. Protein concentration was
quantitated with the BCA protein assay kit (Pierce Biotechnology).
Cell extracts equivalent to 50 mg of protein was subjected to lipid
extraction with chloroform-methanol as described by Weir et al.
[43]. The lipid extracts were analysed by LC-MS using the same meth-
odology as for the plasma samples, except that the number of quanti-
tated lipid species for LNCaP and 22Rv1 were less comprehensive
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kyldiacylglycerol [TG(O)] species. Lipid levels (pmol/mg protein)
were normalised using the Probabilistic Quotient Normalisation
method as for the plasma lipidomic analysis, with final values
expressed as log2 of pmol/mg protein for statistical analysis.
2.15. Statistics
Radiological progression-free survival (rPFS) and OS time were
calculated using SPSS (version 25) as the time from the date of com-
mencing treatment to the date of the event, and censored at the date
of last follow-up if the event has not occurred. The association of
plasma lipid levels with rPFS or OS was determined by univariable
Cox regression (R package survival, v2.44-1.1). Unique plasma lipid
profiles were identified by latent class analysis (LCA) of the levels of
prognostic lipids categorised into quartiles (R package poLCA, v1.4.1)
[13]. LCA is a non-supervised method that identifies class member-
ship (lipid profiles) using the observed variables. The most parsimo-
nious number of lipid profiles was determined with the minimum
Bayesian Information criterion. Differences in plasma lipid levels
between groups of patients were determined by t-test, which was
performed with the R package multtest (v2.41.0). Principal compo-
nents analysis (PCA) was performed using the R package ggfortify
(v0.4.11) on pre-treatment plasma lipidomic profiles to determine if
there were any underlying metabolic differences amongst the
patients. Enrichment of lipid types was determined by one-sided
Fisher’s exact tests using the R package bc3net (v1.04).
The frequency of AR aberrations between groups of patients was
compared by Fisher’s exact test using Prism 9 (GraphPad Software).
The association of AR aberrations, lipid profiles, or sphingolipid gene
aberrations with rPFS, OS, or treatment duration was determined by
univariable Cox regression as above. Median survival time was also
calculated with the R package survival. Kaplan-Meier curves were
drawn with the R package survminer (v0.4.6).
To identify sphingolipid genes that are associated with ARSI resis-
tance, a list of genes associated with sphingolipid metabolism was
compiled from the KEGG pathway database, NCBI Gene or literature
(Supplementary S3.1). Data on copy number alterations and mRNA
expression of these sphingolipid genes in mCRPC tumours from tax-
ane-naïve patients receiving ARSI therapy and treatment duration
were obtained from the genomic study by the SU2C/PCF Dream Team
(Abida et al.)[44] through CbioPortal (www.cbioportal.org). Copy
number alteration data with ARSI treatment duration information
were available for the tumours of 108 men, of which 47 also have
RNA-seq data. To overcome missing or zero values in the mRNA
expression data (FPKM capture), the value of 1 was added to the
mRNA expression values of all the samples, and then the dataset was
transformed to log2. Cox regression and survival analyses in relation
to ARSI duration were performed on men classified by copy number
gain or mRNA expression (low versus high expression) of each sphin-
golipid gene in the presence or absence of AR gain, using the R pack-
age survival (v2.44-1.1).
IC50 (inhibitory concentration causing a 50% response) of ENZ
dose response curves for cell lines was calculated using the log(inhib-
itor) vs response (three parameters) method in Prism 9. The log IC50
of two curves were compared using the Extra sum-of squares F test
(Prism 9). T-tests for cell line and ex vivo assays were also performed
with Prism 9, and are unpaired two-tail unless stated otherwise.
Microarray data was normalised with the RMA method using the
Transcriptome Analysis Console (TAC) (v4.0.2, Applied Biosystems).
PCA of the normalised data showed that there were 3 outliers (2 rep-
licates of ABC & 1 replicate of ENZ, Supplementary S6.1). These out-
liers were excluded from the dataset and the files were re-
normalised again for downstream analysis. Differentially expressed
genes from the normalised data were determined using LIMMA with
the TAC software. LIMMA is a moderated t-test for multivariable datathat fits a linear model onto each variable using information from its
neighbours [45]. Probes that could not be mapped to a gene were fil-
tered from the dataset. Genes were considered to be significantly dif-
ferentially expressed between compared treatments if the fold
change was 1.2 fold and p-value <0.05 (unadjusted). P-value cor-
rection was not applied as it was too stringent and reduced the num-
ber of hits (Supplementary S6.2). Gene set enrichment analysis of
differentially expressed genes was performed with the Molecular Sig-
nature Database (MSigDb) [46,47], using the “Investigate Gene Sets”
module which computes the overlap between our list of differentially
expressed genes and the gene sets in MsigDb. Gene symbols were
used as the gene identifiers. The collection of gene sets selected were
Hallmark, KEGG, and Reactome, where analyses for each collection
was performed separately.
Differentially abundant lipids from lipidomic analysis of cell lines
were determined using LIMMA with the R package limma (v3.41.18).
Enrichment analysis of lipid types was performed with bc3net as for
the plasma lipids.
Heatmaps were drawn with the R package pheatmap (v1.0.12). R
version 3.6.0 was used for all analyses requiring R packages. Bar
graphs were drawn with Prism 9, and represent the average § stan-
dard error of replicates. P-values < 0¢05 were considered as statisti-
cally significant.2.16. Role of funders
Funding sources were not involved in study design, data collec-
tion, data analysis, data interpretation or writing of the report.3. Results
3.1. Elevated circulating ceramides are associated with ARSI resistance
To identify circulating lipids that are associated with ARSI resis-
tance, lipidomic analysis was performed on plasma samples collected
before commencement of ARSI therapy from an Australian cohort of
132 patients (Table 1, Fig. 1b). The median follow-up time of the
patients was 18¢5 months (1st quartile = 11¢2 months, 3rd
quartile = 26¢5 months), with 87 radiological progression events and
75 deaths.
A total of 762 lipid species comprising 48 different lipid types
were detected in the plasma samples. Principal components analysis
of the pre-treatment plasma lipidomic profiles did not show any dis-
tinct groupings of the samples, indicating that there were no major
variation or underlying metabolic differences between the treatment
groups that may confound statistical analyses (Fig. 1c). Amongst the
48 different lipid types, only the total levels of all ceramide (Cer(d)),
diacylglycerol (DG) or alkylphosphatidylethanolamine (PE(O)) spe-
cies were significantly associated with rPFS (Cox regression p  0¢04,
Fig. 1d). Elevated total levels of all ceramide species were associated
with shorter rPFS (HR=2¢51, 95% CI 1¢155¢49, p = 0¢02, Fig. 1d). Ele-
vated total levels of ceramide species or that of four other types of
sphingolipids (glycosphingolipids [Hex3Cer, GM3, GM1], sphingo-
myelin [SM]) were associated with shorter OS (Cox regression
p  0¢03, Fig. 1d).
Assessment of the levels of individual lipid species revealed that
99 lipid species were significantly associated with rPFS (Cox regres-
sion p< 0¢05, Supplementary S1.1 & S1.3). Lipid species with elevated
levels that were associated with shorter rPFS were significantly
enriched for ceramide and diacylglycerol (Fisher’s exact test p = 0¢04,
Supplementary S1.2). Amongst all the sphingolipids, elevated levels
of ceramides and GM3 gangliosides were the only species that were
associated with shorter rPFS (Cox regression p < 0¢05, Fig. 1e). The
elevated levels of several other sphingolipids including ceramides
were associated with shorter OS (Cox regression p < 0¢05, Fig. 1e).
Table 1














Age (years), median [Q1, Q3] 74 [67, 81] 74 [67, 80]
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Haemoglobin (g/L), median [Q1, Q3] 127 [118, 137] 126 [118, 138]



































































Definition of abbreviations: Q1, 1st quartile; Q3, 3rd quartile; ADT, androgen depri-
vation therapy
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species associated with rPFS was performed to further demonstrate
the prognostic role of circulating ceramide levels. The analysis classi-
fied the patients into two groups with different prognoses, referred
to as Lipid Profiles 1 and 2. Patients with Lipid Profile 2 had shorter
rPFS (HR=2¢28, 95% CI=453¢59, p = 0¢0005) and shorter OS
(HR=2¢26, 95% CI=1¢433¢56, p = 0¢0005) than patients with Lipid
Profile 1 (Fig. 1f & g). Additionally, patients with Lipid Profile 2 had
higher levels of several ceramide species (two-tail t-test p < 0¢05,
Fig. 1h, Supplementary S1.3) including Cer(d18:1/24:1), a key compo-
nent of our previously identified circulating lipid signature in doce-
taxel-treated mCRPC [24,25].
Fifteen patients receiving ENZ and five patients receiving abirater-
one also had plasma samples collected at the time of progression.
These plasma samples were subjected to lipidomic analysis together
with the baseline samples. Although treatment-specific effects on the
lipidomic profiles cannot be conclusively determined with such a
small number of patients, differences in the levels of 84 lipids were
identified between both treatments (Supplementary S1.5). The levelsof dehydrocholesteryl ester, alkenylphosphatidylethanolamine and
dehydrodesmosteryl ester were lower in plasma from ENZ-treated
patients, whereas the levels of oxidised lipids and dihydroceramide
were higher. However, the total levels of ceramide were not signifi-
cantly different between both treatments (ENZ/abiraterone fold
difference = 1¢099, t-test p = 0¢44).
Overall, our lipidomic analysis showed that elevated circulating
ceramides were associated with ARSI resistance in mCRPC patients.3.2. Elevated circulating ceramides are associated with worse prognosis
in the presence of AR gene aberrations
Somatic AR gene aberrations were determined through next-gen-
eration sequencing of cfDNA of the baseline plasma samples (Predi-
cine, Inc. [41]). Only 77 of the 132 patients had detectable cfDNA for
sequencing. This subset of patients had similar clinical characteristics
to the full cohort (Table 1). Somatic AR gene aberrations were found
in 33 of these 77 patients (43%), and consisted of gains (26 patients,
34%) and missense mutations (12 patients, 16%) (Fig. 2a, Supplemen-
tary S2.1). Consistent with previous studies [7,41], the presence of
any of these AR aberrations was associated with shorter rPFS
(HR=2¢10, 95% CI 1¢163¢79, p = 0¢01), shorter prostate-specific anti-
gen-progression-free survival (HR=2¢40, 95% CI=1¢414¢08,
p = 0¢001), decreased treatment duration (HR=2¢26, 95%
CI=1¢353¢80, p = 0¢002) and shorter OS (HR=3¢62, 95% CI=1¢886¢97,
p < 0¢001).
The circulating levels of 17 ceramide species were higher in
patients with AR aberrations than those without, and 12 of these cer-
amide species were also elevated amongst patients with the poor
prognostic Lipid Profile 2 (Fig. 2b, two-tail t-test p < 0¢05, Supple-
mentary S2.2). Furthermore, AR aberrations were more frequent in
patients with Lipid Profile 2 compared to those with Lipid Profile 1
(58% vs 33%, Fisher’s exact test p = 0¢04) (Fig. 2c), indicating that AR
aberrations are enriched in patients with Lipid Profile 2.
The clinical outcomes of having both Lipid Profile 2 and any AR
aberration were assessed. Patients having both Lipid Profile 2 and
any AR aberration (Group C) had significantly shorter rPFS and signifi-
cantly shorter OS than those having Lipid Profile 1 without an AR
aberration (Group A) (rPFS: median Group A vs C =17¢7 vs 3¢9
months, HR=2¢66, p = 0¢002; OS: median Group A vs C = 34¢4 vs 8¢9
months, HR=6¢83, p < 0¢001)(Fig. 2d, e, Supplementary S2.3). Patients
having both Lipid Profile 2 and any AR aberration (Group C) also had
shorter rPFS and significantly shorter OS than those having either
Lipid Profile 2 or AR aberration (Group B) (rPFS: median Group C vs
B = 8¢3 vs 3¢9 months, HR=1¢47, p = 0¢28; OS: median Group C vs
B = 19¢8 vs 8¢9 months, HR=2¢23, p = 0¢02)(Fig. 2d, e, Supplementary
S2.3).
Overall, elevated circulating ceramides and AR aberrations were
individually associated with worse clinical outcomes with ARSI treat-
ment, and having both of these characteristics conferred a much
poorer prognosis.3.3. Sphingolipid gene aberrations are associated with ARSI resistance in
the presence of AR gain
We next investigated whether somatic aberrations in genes
involved in sphingolipid metabolism were associated with ARSI resis-
tance, by using open-access tumour genomic data of taxane-naïve
mCRPC patients receiving ARSI therapy in the United States [44],
available on cBioPortal. We examined copy number alterations and
mRNA expression of 65 sphingolipid genes in the dataset, consisting
of 108 patients with tumours profiled by whole-exome sequencing,
of which 47 were also profiled by RNA-seq. The length of time that
the patients received ARSI treatment was the only indicator of ARSI
resistance available for this cohort. AR gain (high level) was
Fig. 2. Elevated circulating levels of ceramides and somatic aberrations of sphingolipid genes are associated with worse response to ARSI in the presence of AR aberrations: (a) AR
aberrations in mCRPC study cohort; (b) heatmap of plasma levels of ceramide species in patients grouped by AR aberration status; (c) percentage of patients with AR aberrations
according to lipid profile; (d & e) Kaplan-Meier curves of rPFS and OS of patients grouped by AR aberration status and Lipid Profile 2; (f) metabolic pathway of de novo ceramide syn-
thesis and ceramide-S1P signalling axis with sphingolipid gene aberrations (red = copy number gain; underlined = high mRNA) that are associated with worse ARSI treatment dura-
tion in the presence of AR aberrations, and examples of their Kaplan-Meier curves.
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H.-M. Lin et al. / EBioMedicine 72 (2021) 103625 9associated with shorter duration of ARSI treatment (HR=1¢28, 95%
CI=1¢031¢58, p = 0¢02).
Copy number gain (low and high level) or elevated mRNA expres-
sion of six sphingolipid-related genes were significantly associated
with shorter ARSI treatment duration in men with mCRPC (Supple-
mentary S3.2, Cox regression p < 0¢05). However, men having both
AR gain and copy number gain of any of 26 sphingolipid genes have
shorter ARSI treatment duration compared to men with none of these
genetic aberrations (Cox regression p < 0¢05, Fig. 2f [Group C vs A],
Supplementary S3.3). Sixteen of these 26 sphingolipid genes are
involved in the ceramide-S1P signalling axis and de novo ceramide
synthesis (Fig. 2f). Men who had both AR gain and copy number gain
of any of 9 of these 26 sphingolipid genes also had significantly
shorter ARSI treatment duration compared to men with only one of
these genetic aberrations (Cox regression p  0¢05, Fig. 2f [Group C vs
B], Supplementary S3.3). Five of these 9 sphingolipid genes are
involved in the ceramide-S1P signalling axis and de novo ceramide
synthesis  KDSR, ACER3, SPNS2, PLPP2, S1PR4.
Elevated mRNA expression of five sphingolipid genes also con-
ferred shorter ARSI treatment duration if any were present with AR
gain, compared to the absence of both genetic aberrations (Cox
regression p < 0¢05, Supplementary S3.4). Four of these genes were
amongst the 26 with copy number gain that were associated with
shorter ARSI duration in the presence of AR gain  CERS2, SPTSSA,
GLB1, GBA.
Overall, these associations suggest that copy number gain or ele-
vated mRNA expression of sphingolipid genes in mCRPC tumours
may be mediating ARSI resistance induced by AR gain through
enhanced ceramide-S1P signalling from increased de novo ceramide
synthesis, conversion of ceramide into S1P and expression of S1P
receptors.
3.4. SPHK inhibition enhances ENZ efficacy in vitro
To investigate the potential contribution of the ceramide-S1P sig-
nalling axis to ENZ resistance in tumour cells, AR-positive PC cell lines
LNCaP, C42B and 22Rv1 were treated with ENZ alone or in combina-
tion with the SPHK inhibitors, PF-543 (PF5) or ABC294640 (ABC),
which inhibit SPHK1 and SPHK2, respectively (Fig. 3a). All three cell
lines express AR, SPHK1 and SPHK2 (Fig. 3b). However, C42B and
22Rv1 exhibit greater resistance to ENZ than LNCaP (Fig. 3c). Both
SPHK inhibitors reduced PC cell viability, but their effects were
greater when combined with ENZ (t-test p < 0¢0001, Fig. 3d). Both
SPHK inhibitors also significantly decreased the IC50 of ENZ in all
three cell lines (F-test p < 0¢008, Fig. 3e), except for PF5 treatment of
LNCaP. The combined treatments of ENZ with either SPHK inhibitor
also resulted in significantly less colony formation than individual
treatments (one-tail t-test p < 0¢05, Fig. 3f).
ENZ and SPHK inhibition reduced cell viability by decreasing cell
proliferation and/or enhancing apoptosis or necrosis, depending on
the cell line (t-test p < 0¢05, Fig. 3g). ABC alone (SPHK2 inhibition) or
in combination with ENZ caused a higher percentage of LNCaP and
C42B cells to remain in the G1 phase compared to control or ENZ
treatment (t-test p  0¢02). PF5 (SPHK1 inhibition) caused a higher
percentage of LNCaP cells to remain in the G1 phase compared to
control treatment (t-test p = 0¢009). Either SPHK inhibitor alone or in
combination with ENZ increased apoptosis/necrosis in all three cell
lines, compared to ENZ or control treatment (t-test p < 0¢05). PF5
induced autophagy in 22Rv1, which is demonstrated by the conver-
sion of LC3B-I into LC3B-II (Fig. 3h), indicating that 22Rv1 also under-
goes autophagic cell death in response to SPHK1 inhibition. AR levels
were not altered by the SPHK inhibitors or ENZ treatment in any of
the cell lines (Supplementary S4.4).
Transient knock-down of AR expression with synthetic small
interfering RNA (siRNA) in combination with either SPHK inhibitor
also resulted in decreased cell viability in all three cell lines(Supplementary S5), thus confirming that inhibition of AR signalling
in combination with SPHK inhibition decreases cell viability.
3.5. SPHK inhibition enhances ENZ efficacy ex vivo
The efficacy of SPHK inhibition in overcoming intrinsic ENZ resis-
tance in prostate tissues was determined by treating ex vivo cultures
of fresh tissue biopsies of the prostate from 14 patients with localised
PC undergoing radical prostatectomy. After 48 h of culture in ENZ
and PF5 or ABC, the proliferation of cancer cells and adjacent benign
cells were assessed by Ki67 immunostaining and compared to control
(DMSO vehicle). Explants from 11 patients showed increased Ki67
expression with ENZ treatment compared to control (DMSO vehicle)
(Fig. 3i). SPHK inhibitors prevented the ENZ-induced increase in Ki67
expression (paired one-tail t-test p  0¢003, Fig. 3i), suggesting that
SPHK inhibition can overcome ENZ resistance in prostate cancer tis-
sue.
3.6. ENZ combined with SPHK inhibition enhances ER stress and
lipogenesis gene expression
To further investigate the mechanism of SPHK inhibition on
enhancing ENZ efficacy, transcriptomic analysis with Clariom D (Affy-
metrix) microarrays was performed on C42B cells treated for 6 h with
ENZ, SPHK inhibitors (ABC or PF5) or vehicle control (DMSO). This
early timepoint was chosen to identify changes in gene expression
and signaling pathways prior to apoptosis and cell death processes.
Gene set enrichment analysis was performed on differentially
expressed genes to identify the relevant cellular functions and signal-
ling pathways (Supplementary S6.3, S6.4). As expected, androgen-
regulated genes were downregulated by ENZ treatment (LIMMA
p < 0¢05, Supplementary S6.3 & S6.4), indicating that AR is still
responsive to ENZ despite C42B being more resistant to ENZ than the
parental cell line, LNCaP. The separate contribution of ENZ and SPHK
inhibition to the combination treatments was dissected by examining
the overlap of differentially expressed genes from the comparisons of
“ENZ versus control”, “SPHK inhibition versus control” and “combina-
tion treatment versus ENZ” (Fig. 4a, Supplementary S6.3 & S6.4). The
analyses indicated that upregulation of lipid metabolism and endo-
plasmic reticulum (ER) stress genes were, respectively, driven by
SPHK1 inhibition (PF5) and ENZ in the combination treatment
(Fig. 4a).
The expression of representative lipid metabolism genes (FASN,
STARD4, HMGCR) and ER stress genes (DDIT3, CHAC1) was validated
using Real-Time Polymerase Chain Reaction (RTPCR) in all three cell
lines (Fig. 4b). PF5 alone and combined with ENZ upregulated the
expression of all three lipid metabolism genes compared to ENZ alone
after 6 or 24 h of treatment in all three cell lines (t-test p  0¢04,
Fig. 4b). ENZ-ABC only increased the expression of FASN in C42B and
HMGCR in 22Rv1 compared to ENZ after 24 h treatment (t-test
p  0¢04, Fig. 4b). ENZ generally decreased the levels of HMGCR and
STARD4, and opposed their upregulation by PF5 or ABC.
ENZ-PF5 enhanced the expression of both ER stress genes com-
pared to ENZ alone in C42B and 22Rv1 (t-test p  0¢04), but not
LNCaP after 6 or 24 h treatment (Fig. 4c). ENZ-ABC enhanced the
expression of both ER stress genes compared to ENZ alone, in all
three cell lines after 6 or 24 h treatment (t-test p  0¢04, Fig. 4c). PF5,
ABC or ENZ alone was sufficient to upregulate the expression of the
ER stress genes compared to control treatment, but their upregula-
tion was further increased by combination treatment (t-test p < 0¢04,
Fig. 4c).
Overall, the transcriptomic data indicate upregulation of lipid syn-
thesis pathways and ER stress by concurrent SPHK inhibition with
ENZ treatment. SPHK1 inhibition (PF5) appears to have a stronger
effect on upregulation of lipid synthesis pathways than SPHK2 inhibi-
tion (ABC).
Fig. 3. ENZ-SPHK inhibition reduces viability of prostate cancer cells (figure abbreviations: C, vehicle control; E, ENZ; P, PF5; A, ABC): (a) sphingosine kinase (SPHK) inhibition  PF5
inhibits SPHK1 which is present in the cytoplasm, whereas ABC inhibits SPHK2 which is predominantly present in the nucleus, thus blocking the conversion of sphingosine into
S1P; (b) representative Western blot confirming the expression of AR, SPHK1 and SPHK2 (original whole blot displayed in Supplementary S4); (c) ENZ dose-response curves demon-
strating differences in sensitivity of the cell lines; (d) cell viability after 96 h treatment of SPHK inhibitors § ENZ, *t-test p < 0¢0001; (e) ENZ dose-response curves of combination
treatment; (f) representative photos of colony formation, and number of colonies formed after treatment with SPHK inhibitors § ENZ, *one-tail t-test p < 0.05; (g) distribution of
cell cycle phases and percentage of apoptotic/necrotic cells after 48 h treatment with SPHK inhibitors § ENZ, *t-test p  0¢05 for at least one of the subsets; (h) representative West-
ern blots of SPHK1, SPHK2 and LC3B (original whole blots displayed in Supplementary S4); (i) percentage of Ki67 in explants cultured from fresh primary prostate tumours of 11
patients (mean§ standard error), *paired t-test p  0¢04. Dose response curves and bar graphs are mean§ standard error of 3-4 replicates unless shown otherwise. P-values are cal-
culated by two-tail t-test, unless stated otherwise.
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Fig. 4. Transcriptomic changes induced by ENZ-SPHK inhibition in cell lines (figure abbreviations: C, vehicle control; E, ENZ; P, PF5; A, ABC): (a) Venn diagram of upregulated genes
in C42B treated with ENZ, PF5 or control for 6 h, and heatmap of the expression of enriched genes from the Venn diagram partitions; (b) & (c) RTPCR quantitation of representative
genes associated with lipid metabolism and ER stress in C42B, 22Rv1 and LNCaP cells after 6 or 24 h treatment. P-values are from two-tail t-tests. Bar graphs are mean § standard
error.
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Fig. 5. Lipidomic changes induced by ENZ-SPHK1 inhibition (PF5) and the proposed mechanism of the treatments (abbreviations in figures: E, ENZ; P, PF5; Sph, sphingosine; DHT,
dihydrotestosterone; AR, androgen receptor; TG, triacylglycerol): (a) lipid types with significantly increased total levels in C42B cells after 24 h treatment (LIMMA p-values); (b)
Venn diagram of abundant lipids in C42B treated with ENZ, PF5 or control for 24 h, and heatmap of the levels of enriched lipids from the Venn diagram partitions; (c) representative
Western blots of SREBP1 activation after 6 h treatment, and densitometry analyses of the bands (one-tail paired t-test; whole western blots with markers are diplayed in Supple-
mentary S9. Bar graphs are mean § standard error).
12 H.-M. Lin et al. / EBioMedicine 72 (2021) 1036253.7. ENZ combined with SPHK inhibition increases triacylglycerol levels
Given that ENZ and SPHK inhibitors altered the expression of lipid
synthesis genes, we next determined which lipids were affected by
performing lipidomic analysis (764 lipid species) of C42B cells treated
for 24 h with ENZ, PF5, ABC or DMSO vehicle control. As expected,
SPHK1 inhibition by PF5 and ENZ-PF5 increased the total levels of
sphingosine in C42B compared to control (LIMMA p < 0¢0001,
Fig. 5a), consistent with the inhibition of sphingosine phosphoryla-
tion. However, accumulation of sphingosine was not observed for
ABC or ENZ-ABC treatment (Supplementary S7.3). Although S1P was
measured, changes were not detected in any of the treatments, possi-
bly due to its extracellular release and characteristically short half-
life [48].
Compared to ENZ treatment, ENZ-PF5 (SPHK1 inhibition) signifi-
cantly increased the total levels of lysophosphatidylinositol (LPI), tri-
acylglycerol (TG) and monoalkyldiacylglycerol [TG(O)], whereas ENZ-
ABC (SPHK2 inhibition) only increased the total levels of TG (LIMMA
p  0¢02; Fig. 5a, Supplementary S7.2, S7.3). Enrichment analysis of
individual lipid species showed that the lipids upregulated by ENZ-
PF5 compared to ENZ were significantly enriched for TG, TG(O), diac-
ylglycerol (DG), LPI and phosphatidylinositol (PI) (Fisher’s exact test
p < 0¢05, Supplementary S7.4). Upregulation of these lipid types is
consistent with enhanced synthesis of TG, as DG is a precursor of TG,
whereas LPI and PI share the same phosphatidic acid precursor as DG
(Supplementary S7.5).
The separate contribution of ENZ and PF5 to the lipidomic changes
caused by combination treatment were dissected by examining the
overlap of differential lipids from the comparisons of “ENZ versuscontrol”, “PF5 versus control” and “ENZ-PF5 versus ENZ”. The analysis
showed that ENZ or PF5 treatments alone was sufficient to increase
the levels of TG, with an even higher increase by ENZ-PF5 combina-
tion (LIMMA p < 0¢05, Fig. 5b). The ENZ-PF5 combination also
increased the levels of additional TG species that was not enhanced
by either individual treatment (LIMMA p < 0¢05, Fig. 5b). The number
of TG species upregulated by ENZ-ABC compared to ENZ was much
lower than that for ENZ-PF5 (Supplementary S7.6).
Although transcriptomic analysis and RT-PCR validation showed
enhanced expression of cholesterol synthesis genes by ENZ-PF5 com-
bination in C42B cells, the levels of free cholesterol were not altered.
A targeted lipidomic analysis was then performed on LNCaP and
22Rv1 to examine the levels of TG, TG(O) and cholesterol, after 24 h
of treatment with SPHK inhibition and ENZ. In contrast to C42B, total
TG levels were not altered by PF5, ABC or combination with ENZ.
Instead, cholesterol levels were increased by PF5 and ENZ-PF5 com-
pared to ENZ in both cell lines, whereas TG(O) levels were elevated
by ENZ-PF5 and ENZ-ABC compared to ENZ in LNCaP (t-test p  0¢04,
Supplementary S8).
Overall, these findings indicate that combined ENZ and SPHK
treatment increased lipid synthesis and accumulation which may be
causing lipotoxicity-induced cell death, where the type of accumu-
lated lipids vary according to the cell lines.
3.8. ENZ combined with SPHK1 inhibition increases SREBP activation
Transcriptomic and lipidomic analysis demonstrated that SPHK
inhibitors alone and in combination with ENZ enhanced lipogenesis
in the PC cell lines. Several of the lipid synthesis genes are known to
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(Fig. 4a), which are transcription factors that stimulate lipogenesis
gene expression [49]. Proteolytic cleavage of SREBP into a mature
active form is required for transcription. SREBP1 stimulates both lipo-
genic and cholesterogenic gene expression, whereas SREBP2 regu-
lates cholesterogenic expression.
To determine if enhanced SREBP activity contributes to ENZ-SPHK
inhibition-induced lipogenesis, the expression of SREBP1 and SREBP2
in PC cells treated with ENZ, PF5, ABC or vehicle control for 6 h were
analysed by Western blot. ENZ-PF5 (SPHK1 inhibition) treatment
increased the levels of mature SREBP1 compared to ENZ alone in
C42B (one-tail paired t-test p = 0¢005) and in LNCaP (one-tail paired
t-test p = 0¢03)(Fig. 5d), but not in 22Rv1 cells (one-tailed paired t-
test p = 0¢41). The levels of mature SREBP1 in PF5 or ENZ-PF5 treated
C42B cells were also higher than that of control (one-tail t-test
p = 0¢002 and 0¢01, respectively). ENZ-ABC (SPHK2 inhibition) only
increased the levels of mature SREBP1 in LNCaP compared to ENZ
(one-tail paired t-test p = 0¢007, Supplementary S9.2).
Overall, these findings suggest that ENZ-PF5 (SPHK1 inhibition)
induced-lipogenesis in C42B and LNCaP is mediated by increased
SREBP1 activation, whereas a different mechanism of enhanced lipo-
genesis is operating in 22Rv1.
4. Discussion
Treatment resistance to ARSI remains a significant clinical prob-
lem for men with mCRPC. Our study has demonstrated that a circu-
lating lipid profile consisting of elevated levels of ceramides is
associated with shorter rPFS on ARSI treatment and somatic AR aber-
rations. Furthermore, having both AR aberrations and a lipid profile
of elevated ceramides confer a much poorer prognosis with regards
to both rPFS and OS. Likewise, having both AR gain and somatic gene
aberrations in sphingolipid metabolism in mCRPC tumour tissue sig-
nificantly reduces ARSI treatment duration. These associations indi-
cate that ARSI resistance is mediated not only by genetic anomalies
in AR, but also by perturbations in sphingolipid metabolism, and thus
patients may benefit from combination therapy targeting both AR
signalling and sphingolipid metabolism. Indeed, our study demon-
strated that targeting the ceramide-S1P signalling axis by chemical
inhibition of SPHK1 or SPHK2 can enhance the efficacy of ENZ
through increased cancer cell death.
Elevation of circulating ceramides in men with poorer prognosis
observed in our study could be a bystander effect of enhanced liver/
tumour production; and/or could be contributing to ARSI resistance
and tumour progression through their uptake by the tumour fol-
lowed by conversion into pro-survival S1P. In support of the latter,
we found that increased mRNA expression or copy number gain of
genes related to the ceramide-S1P signalling axis in mCRPC tumours
were associated with shorter ARSI treatment duration especially in
the presence of AR gain. Regardless of the source of the circulating
ceramides, their increased levels are associated with poorer progno-
sis especially in the presence of AR aberrations, suggesting that the
ceramide-S1P signaling axis promotes ARSI resistance and is a poten-
tial therapeutic target in mCRPC.
Several studies have demonstrated that inhibition of S1P produc-
tion by SPHK can decrease cancer growth [10,36,50,51]. Sphingosine
itself is pro-apoptotic, thus its accumulation from SPHK inhibition
may be triggering apoptosis [52]. However, our study showed that
the enhanced cell death by the combination of ENZ with SPHK inhibi-
tion may be occurring through enhanced ER stress and lipogenesis,
with the latter mediated by SREBP1 in the case of SPHK1 inhibition
by PF5. The ER is the main site of lipid synthesis and protein folding.
Disruption of ER homeostasis, such as accumulation of unfolded pro-
teins and alterations in ER lipid composition, causes ER stress and
activates the unfolded protein response to restore homeostasis [53].
Failure to restore ER homeostasis results in apoptosis and cell death[53]. Our study showed that SPHK inhibition or ENZ treatment alone
was sufficient to upregulate the expression of ER stress genes com-
pared to vehicle control. ER stress could be a survival mechanism of
ENZ resistance as Sheng et al (2019) showed that AR signalling acti-
vated MYC signalling through the unfolded protein response to pro-
mote PC cell growth [54]. SPHK inhibition may be causing ER stress
through the accumulation of sphingosine, as sphingosine and SPHK
inhibition can disrupt endocytic membrane trafficking [55]. Increased
activation of lipogenesis genes and enhanced levels of triacylglycerol
or cholesterol by SPHK1 inhibition (PF5) in PC cells in our study is
consistent with other reports that ER stress can induce SREBP-medi-
ated lipotoxicity [56,57]. Therefore, the intensification of ER stress
from both SPHK inhibition and ENZ may be causing the unfolded pro-
tein response to activate apoptosis instead of restoring homeostasis.
The connection between sphingolipid metabolism and triacylgly-
cerol metabolism has been demonstrated by studies on mice with
S1P-lyase (SGPL1) [58] or acid sphingomyelinase (ASM) deficiency
[59]. SGPL1 degrades S1P, whereas ASM (aka SMPD1) hydrolyses
sphingomyelin into ceramide. Mice deficient in either enzymes not
only display perturbed hepatic levels of sphingolipids, but also an
increase in hepatic triacylglycerol levels and reduced body fat com-
pared to their wildtype counterparts (sgpl1/ mice have elevated
ceramide, sphingomyelin, sphingosine; asm//ldlr/ mice have ele-
vated ceramide, dihydroceramide, sphingomyelin; ldlr = low density
lipoprotein receptor) [58,59]. Additionally, supplementation of liver
cells with palmitate (precursor for triacylglycerol and de novo cer-
amide synthesis) stimulated triacylglycerol and sphingolipid synthe-
sis, whereas inhibition of ASM shifted the incorporation of palmitate
from triacylglycerol to ceramide [59]. Therefore, the increased level
of triacylglycerol induced by ENZ-SPHK inhibition is consistent with
the redirection of lipid precursors towards triacylglycerol synthesis
to compensate for the accumulation of sphingosine.
Compared to SPHK1 inhibition (PF5), the effects of SPHK2 inhibi-
tion (ABC) on triacylglycerol levels were less apparent. Furthermore,
sphingosine levels were not significantly increased by SPHK2 inhibi-
tion unlike SPHK1 inhibition, suggesting that phosphorylation of
sphingosine into S1P is mainly catalysed by cytoplasmic SPHK1
rather than nuclear SPHK2. Thus, accumulation of cytoplasmic sphin-
gosine by SPHK1 inhibition may be the main driver of lipogenesis-
induced ER stress, resulting in a larger increase of triacylglyerols lev-
els compared to SPHK2 inhibition.
The transcriptomic and lipidomic changes produced by ENZ-
SPHK2 inhibition also differed from SPHK1 inhibition, which may be
related to the different roles of S1P in the nucleus versus cytoplasm.
S1P produced in the nucleus by SPHK2 can enhance histone acetyla-
tion by inhibiting the activity of histone deacetylases HDAC1 and
HDAC2 [60]. Histone acetylation is typically associated with open
chromatin conformation and increased gene expression, thus inhibi-
tion of SPHK2 may be disrupting the regulation of gene expression by
histone deacetylases. Additionally, a different mechanism of
enhanced lipogenesis under SPHK inhibition appears to be occurring
for 22Rv1 which did not display SREBP1 activation, and underwent
autophagy with SPHK1 inhibition. These findings demonstrate the
heterogeneity of prostate cancer cells and the importance of studying
different cell lines.
ABC, also known as opaganib, is the only sphingosine kinase
inhibitor that has undergone clinical trials [61]. PF5 was developed
by Pfizer, but never entered human trials. ABC has undergone a Phase
1 study for advanced solid tumours and was well-tolerated at 500 mg
bid with the most common drug-related toxicities being nausea,
vomiting and fatigue [61]. There are ongoing Phase 2 clinical trials
with ABC in cancer and COVID-19.
The limitations of our study include the lack of ethnic diversity in
the cohorts and the need for an independent validation cohort. More
than 90% of the study cohort were Caucasians, and recruited from an
Australian population, in which there is little African ancestry. The
14 H.-M. Lin et al. / EBioMedicine 72 (2021) 103625range of life-prolonging treatment used is comparable to other devel-
oped countries in Europe and North America. However, the prognos-
tic relationship of the circulating lipids with ARSI resistance will
require validation in an independent external cohort of men of other
ethnicity who may have divergent results.
In conclusion, elevated circulating ceramides were associated
with ARSI resistance and confer a worse prognosis in the presence of
AR aberrations. SPHK inhibition enhanced ENZ efficacy in PC cells.
Overall, our findings indicate that ARSI resistance is mediated not
only by genetic anomalies in AR, but also by perturbations in sphingo-
lipid metabolism, and thus men with mCRPC might benefit from
combination therapy targeting both AR signalling and sphingolipid
metabolism. Further investigation with prospective clinical trials is
warranted.
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